Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 29-Jan-13 8:07 PM View:  | Armer Thomas A Chief Scientific Officer Director | MAP Pharmaceuticals, Inc. (MPLPE) | 25-Jan-15 | Payment of Exercise | 1,034 | $24.75 | $25,591.50 | (< 1%) 131.91K to 130.88K | |
| 04-Mar-13 8:15 PM View: | Gianakakos Anastasios SVP, Chief Business Officer | MAP Pharmaceuticals, Inc. (MPLPE) | 01-Mar-13 | Disposition (change in control) | 18,438 | $25.00 | $460,950.00 | (100%) 18.44K to 0 | |
| 04-Mar-13 8:28 PM View: | Chai Christopher Y SVP, Chief Financial Officer | MAP Pharmaceuticals, Inc. (MPLPE) | 01-Mar-13 | Disposition (change in control) | 14,220 | $25.00 | $355,500.00 | (100%) 14.22K to 0 | |
| 04-Mar-13 8:13 PM View: | Borland Scott SVP, Neurology Franchise | MAP Pharmaceuticals, Inc. (MPLPE) | 01-Mar-13 | Disposition (change in control) | 12,951 | $25.00 | $323,775.00 | (100%) 12.95K to 0 | |
| 04-Mar-13 8:16 PM View: | Friedman Charlene A SVP, Gen Counsel & Sec | MAP Pharmaceuticals, Inc. (MPLPE) | 01-Mar-13 | Disposition (change in control) | 4,229 | $25.00 | $105,725.00 | (100%) 4.23K to 0 | |
| 05-Mar-13 2:01 PM View: | McPherron Matthew V Director | MAP Pharmaceuticals, Inc. (MPLPE) | 01-Mar-13 | Disposition (change in control) | 2,999,530 | $25.00 | $74,988,200.00 | (100%) 3.0M to 0 | |
| 04-Mar-13 8:14 PM View: | Kellerman Donald J SVP,Clinical Dev & Med Affairs | MAP Pharmaceuticals, Inc. (MPLPE) | 01-Mar-13 | Disposition (change in control) | 3,795 | $25.00 | $94,875.00 | (100%) 3.79K to 0 | |
| 04-Mar-13 8:10 PM View: | Ward Scott R Director | MAP Pharmaceuticals, Inc. (MPLPE) | 01-Mar-13 | Disposition (change in control) | 2,000 | $25.00 | $50,000.00 | (100%) 2.0K to 0 | |
| 04-Mar-13 8:17 PM View: | Armer Thomas A Chief Scientific Officer Director | MAP Pharmaceuticals, Inc. (MPLPE) | 01-Mar-13 | Disposition (change in control) | 222,676 | $25.00 | $5,566,900.00 | (100%) 222.68K to 0 | |
| 04-Mar-13 8:18 PM View: | Nelson Timothy S President and CEO Director | MAP Pharmaceuticals, Inc. (MPLPE) | 01-Mar-13 | Disposition (change in control) | 38,740 | $25.00 | $968,500.00 | (100%) 38.74K to 0 | |
| 04-Mar-13 7:40 PM View: | Henwood Geraldine Director | MAP Pharmaceuticals, Inc. (MPLPE) | 28-Feb-13 | Option Exercise | 10,000 | $12.06 | $120,650.00 | 100% 0 to 10.0K | |
| 04-Mar-13 7:41 PM View: | Gianakakos Anastasios SVP, Chief Business Officer | MAP Pharmaceuticals, Inc. (MPLPE) | 28-Feb-13 | Planned Private Option Sale | 20,000 | $25.00 | $500,000.00 | (52%) 38.44K to 18.44K | |
| 04-Mar-13 7:40 PM View: | Henwood Geraldine Director | MAP Pharmaceuticals, Inc. (MPLPE) | 28-Feb-13 | Planned Private Option Sale | 10,000 | $25.00 | $250,000.00 | (100%) 10.0K to 0 | |
| 04-Mar-13 7:41 PM View: | Gianakakos Anastasios SVP, Chief Business Officer | MAP Pharmaceuticals, Inc. (MPLPE) | 28-Feb-13 | Option Exercise | 20,000 | $10.37 | $207,400.00 | 108% 18.44K to 38.44K | |
| 04-Feb-13 6:07 PM View: | Kellerman Donald J SVP,Clinical Dev & Med Affairs | MAP Pharmaceuticals, Inc. (MPLPE) | 01-Feb-13 | Private Sale (Planned) | 1,429 | $24.73 | $35,339.20 | (29%) 4.91K to 3.48K | |
| 29-Jan-13 8:07 PM View: | Armer Thomas A Chief Scientific Officer Director | MAP Pharmaceuticals, Inc. (MPLPE) | 26-Jan-13 | Option Exercise | 2,250 | -- | -- | 2% 130.88K to 133.13K | |
| 29-Jan-13 7:51 PM View: | Chai Christopher Y SVP, Chief Financial Officer | MAP Pharmaceuticals, Inc. (MPLPE) | 26-Jan-13 | Payment of Exercise | 873 | $24.75 | $21,606.80 | (6%) 14.77K to 13.9K | |
| 29-Jan-13 7:51 PM View: | Kellerman Donald J SVP,Clinical Dev & Med Affairs | MAP Pharmaceuticals, Inc. (MPLPE) | 26-Jan-13 | Payment of Exercise | 871 | $24.75 | $21,557.20 | (15%) 5.78K to 4.91K | |
| 29-Jan-13 8:07 PM View: | Armer Thomas A Chief Scientific Officer Director | MAP Pharmaceuticals, Inc. (MPLPE) | 26-Jan-13 | Payment of Exercise | 846 | $24.75 | $20,938.50 | (< 1%) 133.13K to 132.28K | |
| 29-Jan-13 8:27 PM View: | Borland Scott SVP, Neurology Franchise | MAP Pharmaceuticals, Inc. (MPLPE) | 26-Jan-13 | Option Exercise | 1,900 | -- | -- | 17% 11.16K to 13.06K | |
| 29-Jan-13 7:52 PM View: | Friedman Charlene A SVP, Gen Counsel & Sec | MAP Pharmaceuticals, Inc. (MPLPE) | 26-Jan-13 | Payment of Exercise | 871 | $24.75 | $21,557.20 | (17%) 5.1K to 4.23K | |
| 29-Jan-13 7:52 PM View: | Friedman Charlene A SVP, Gen Counsel & Sec | MAP Pharmaceuticals, Inc. (MPLPE) | 26-Jan-13 | Option Exercise | 2,250 | -- | -- | 79% 2.85K to 5.1K | |
| 29-Jan-13 7:59 PM View: | Gianakakos Anastasios SVP, Chief Business Officer | MAP Pharmaceuticals, Inc. (MPLPE) | 26-Jan-13 | Option Exercise | 2,250 | -- | -- | 14% 16.05K to 18.3K | |
| 29-Jan-13 7:51 PM View: | Chai Christopher Y SVP, Chief Financial Officer | MAP Pharmaceuticals, Inc. (MPLPE) | 26-Jan-13 | Option Exercise | 2,250 | -- | -- | 18% 12.52K to 14.77K | |
| 29-Jan-13 8:27 PM View: | Borland Scott SVP, Neurology Franchise | MAP Pharmaceuticals, Inc. (MPLPE) | 26-Jan-13 | Private Option Sale | 764 | $24.75 | $18,909.00 | (6%) 13.06K to 12.29K | |
| 29-Jan-13 7:51 PM View: | Kellerman Donald J SVP,Clinical Dev & Med Affairs | MAP Pharmaceuticals, Inc. (MPLPE) | 26-Jan-13 | Option Exercise | 2,250 | -- | -- | 64% 3.53K to 5.78K | |
| 29-Jan-13 7:59 PM View: | Gianakakos Anastasios SVP, Chief Business Officer | MAP Pharmaceuticals, Inc. (MPLPE) | 26-Jan-13 | Payment of Exercise | 846 | $24.75 | $20,938.50 | (5%) 18.3K to 17.45K | |
| 29-Jan-13 8:27 PM View: | Borland Scott SVP, Neurology Franchise | MAP Pharmaceuticals, Inc. (MPLPE) | 25-Jan-13 | Option Exercise | 3,000 | -- | -- | 32% 9.47K to 12.47K | |
| 29-Jan-13 7:52 PM View: | Friedman Charlene A SVP, Gen Counsel & Sec | MAP Pharmaceuticals, Inc. (MPLPE) | 25-Jan-13 | Payment of Exercise | 1,207 | $24.75 | $29,873.20 | (30%) 4.06K to 2.85K | |
| 29-Jan-13 7:52 PM View: | Friedman Charlene A SVP, Gen Counsel & Sec | MAP Pharmaceuticals, Inc. (MPLPE) | 25-Jan-13 | Option Exercise | 2,750 | -- | -- | 210% 1.31K to 4.06K | |
| 29-Jan-13 7:59 PM View: | Gianakakos Anastasios SVP, Chief Business Officer | MAP Pharmaceuticals, Inc. (MPLPE) | 25-Jan-13 | Option Exercise | 2,750 | -- | -- | 19% 14.33K to 17.08K | |
| 29-Jan-13 7:51 PM View: | Nelson Timothy S President and CEO Director | MAP Pharmaceuticals, Inc. (MPLPE) | 25-Jan-13 | Payment of Exercise | 3,652 | $24.75 | $90,387.00 | (9%) 42.39K to 38.74K | |
| 29-Jan-13 7:51 PM View: | Chai Christopher Y SVP, Chief Financial Officer | MAP Pharmaceuticals, Inc. (MPLPE) | 25-Jan-13 | Option Exercise | 2,750 | -- | -- | 25% 10.98K to 13.73K | |
| 29-Jan-13 7:51 PM View: | Kellerman Donald J SVP,Clinical Dev & Med Affairs | MAP Pharmaceuticals, Inc. (MPLPE) | 25-Jan-13 | Option Exercise | 2,750 | -- | -- | 138% 1.99K to 4.74K | |
| 29-Jan-13 7:51 PM View: | Nelson Timothy S President and CEO Director | MAP Pharmaceuticals, Inc. (MPLPE) | 25-Jan-13 | Option Exercise | 9,375 | -- | -- | 28% 33.02K to 42.39K | |
| 29-Jan-13 7:59 PM View: | Gianakakos Anastasios SVP, Chief Business Officer | MAP Pharmaceuticals, Inc. (MPLPE) | 25-Jan-13 | Payment of Exercise | 1,034 | $24.75 | $25,591.50 | (6%) 17.08K to 16.05K | |
| 29-Jan-13 8:07 PM View: | Armer Thomas A Chief Scientific Officer Director | MAP Pharmaceuticals, Inc. (MPLPE) | 25-Jan-13 | Option Exercise | 2,750 | -- | -- | 2% 129.16K to 131.91K | |
| 29-Jan-13 8:27 PM View: | Borland Scott SVP, Neurology Franchise | MAP Pharmaceuticals, Inc. (MPLPE) | 25-Jan-13 | Payment of Exercise | 1,317 | $24.75 | $32,595.80 | (11%) 12.47K to 11.16K | |
| 29-Jan-13 7:51 PM View: | Chai Christopher Y SVP, Chief Financial Officer | MAP Pharmaceuticals, Inc. (MPLPE) | 25-Jan-13 | Payment of Exercise | 1,207 | $24.75 | $29,873.20 | (9%) 13.73K to 12.52K | |
| 29-Jan-13 7:51 PM View: | Kellerman Donald J SVP,Clinical Dev & Med Affairs | MAP Pharmaceuticals, Inc. (MPLPE) | 25-Jan-13 | Payment of Exercise | 1,207 | $24.75 | $29,873.20 | (25%) 4.74K to 3.53K | |
| 25-Jan-13 8:44 PM View: | Armer Thomas A Chief Scientific Officer Director | MAP Pharmaceuticals, Inc. (MPLPE) | 23-Jan-13 | Planned Private Option Sale | 39,620 | $24.76 | $980,991.00 | (21%) 188.78K to 149.16K | |
| 25-Jan-13 8:43 PM View: | Nelson Timothy S President and CEO Director | MAP Pharmaceuticals, Inc. (MPLPE) | 23-Jan-13 | Option Exercise | 80,000 | $0.64 | $51,200.00 | 242% 33.02K to 113.02K | |
| 25-Jan-13 8:44 PM View: | Armer Thomas A Chief Scientific Officer Director | MAP Pharmaceuticals, Inc. (MPLPE) | 23-Jan-13 | Option Exercise | 39,620 | $6.39 | $253,160.00 | 27% 149.16K to 188.78K | |
| 25-Jan-13 8:43 PM View: | Gianakakos Anastasios SVP, Chief Business Officer | MAP Pharmaceuticals, Inc. (MPLPE) | 23-Jan-13 | Planned Private Option Sale | 30,000 | $24.76 | $742,800.00 | (68%) 44.33K to 14.33K | |
| 25-Jan-13 8:44 PM View: | Armer Thomas A Chief Scientific Officer Director | MAP Pharmaceuticals, Inc. (MPLPE) | 23-Jan-13 | Private Sale (Planned) | 20,000 | $24.76 | $495,200.00 | (13%) 149.16K to 129.16K | |
| 25-Jan-13 8:43 PM View: | Nelson Timothy S President and CEO Director | MAP Pharmaceuticals, Inc. (MPLPE) | 23-Jan-13 | Planned Private Option Sale | 80,000 | $24.76 | $1,980,800.00 | (71%) 113.02K to 33.02K | |
| 25-Jan-13 8:43 PM View: | Gianakakos Anastasios SVP, Chief Business Officer | MAP Pharmaceuticals, Inc. (MPLPE) | 23-Jan-13 | Option Exercise | 30,000 | $10.37 | $311,100.00 | 209% 14.33K to 44.33K | |
| 27-Nov-12 2:38 PM View: | Henwood Geraldine Director | MAP Pharmaceuticals, Inc. (MPLPE) | 23-Nov-12 | Planned Private Option Sale | 5,240 | $15.00 | $78,600.00 | (100%) 5.24K to 0 | |
| 27-Nov-12 2:38 PM View: | Henwood Geraldine Director | MAP Pharmaceuticals, Inc. (MPLPE) | 23-Nov-12 | Option Exercise | 5,240 | $2.49 | $13,027.60 | 100% 0 to 5.24K | 59% |
| 24-Jan-13 12:44 PM View: | Kellerman Donald J SVP,Clinical Dev & Med Affairs | MAP Pharmaceuticals, Inc. (MPLPE) | 20-Nov-12 | Acquisition (other) | 557 | $9.89 | $5,510.96 | 39% 1.43K to 1.99K |
